BJMO - volume 11, issue 2, march 2017
L. Decoster MD, PhD, C. Kenis PhD, MSc
The 2016 annual conference of the International Society of Geriatric Oncology took place in Milan, Italy from November 17–19th. More than 450 delegates from 42 countries with a special interest in the care for older patients with cancer attended this conference. The meeting provided an overview of current advances in geriatric oncology.
(BELG J MED ONCOL 2017;11(2):78–80)
Read moreBJMO - volume 10, issue 8, december 2016
Rasschaert M , Papadimitriou K , J. Van den Brande MD, R. Weytjens MD, Peeters M
From October 7th till October 11th, Copenhagen formed the background for the 2016 annual meeting of the European Society for Medical Oncology (ESMO). This report will focus on some of the key studies presented during the meeting, referring to gastrointestinal cancer.
(BELG J MED ONCOL 2016;10(8):290–94)
Read moreBJMO - volume 10, issue 8, december 2016
T. Vermassen PhD, S. Rottey MD, PhD
The central theme of ESMO 2016 was ‘From disease treatment to patient care’, and the congress aimed at further integrating clinical research with patient needs. This report will highlight 9 key studies concerning renal cell carcinoma and metastatic prostate cancer, some of which were presented during one of the presidential sessions of the meeting.
(BELG J MED ONCOL 2016;10(8):295–300)
Read moreBJMO - volume 10, issue 8, december 2016
J. Kerger MD
ESMO 2016 not only reflected the increasing interest in oncology by attracting close to 20.000 participants, but also featured the presentation of several important abstracts that may lead to changes in the daily clinical management of gynaecological cancers. This was especially the case for ovarian carcinomas.
(BELG J MED ONCOL 2016;10(8):301–07)
Read moreBJMO - volume 10, issue 8, december 2016
H. Wildiers MD, PhD, Tom Feys MBA, MSc
(BELG J MED ONCOL 2016;10(8):308–13)
Read moreBJMO - volume 10, issue 8, december 2016
V. Kruse MD, PhD, L. Brochez MD, PhD
Although immunotherapy for melanoma caught a lot of interest at this year ESMO congress, some interesting new data on targeted therapies were presented as well. We have selected 10 abstracts, which, to our opinion, deserve some extra attention.
(BELG J MED ONCOL 2016;10(8):314–18)
Read moreBJMO - volume 10, issue 8, december 2016
Tom Feys MBA, MSc
The main focus of attention at ESMO 2016 in the filed of lung cancer was again the use of checkpoint inhibitors. Two studies evaluating a PD1-inhibitor in the first line treatment of metastatic non-small-cell lung cancer (NSCLC) were presented with conflicting results. In addition to this, positive results with the PD-L1 inhibitor atezolizumab were presented together with promising findings with neo-adjuvant nivolumab in the management of early stage NSCLC. ESMO 2016 also featured important data on (new) targeted agents. In this light, the results of the ASCEND-5 study, assessing the efficacy and safety of ceritinib in patients with advanced ALK+ NSCLC who progressed on prior crizotinib and chemotherapy, were presented. Also the final results of the phase III LUX-Lung 7 study, and of the IMPRESS trial will be discussed in this summary. Finally, data were presented with the MEK inhibitor selumetinib in advanced NSCLC.
(BELG J MED ONCOL 2016;10(8):319–24)
Read more
Top
